ConductScience.org, home

Paper28763548

Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

Lv J and 27 others. JAMA, 2017. Cited by 441 papers, by iCite.

Cite this record

ConductScience Library. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. Papers, record 28763548. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28763548

Download JSON
Disease
IgA glomerulonephritis73 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
PubMed
Journal
JAMA
PubMed
Year
2017
PubMed
Publication types
Journal Article, Multicenter Study, Randomized Controlled Trial
PubMed
Citations, by iCite
441
iCite
Relative citation ratio, by iCite
19.2
iCite
Revised in PubMed
2026-05-18
PubMed

Authors28

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lv JJicheng
2Zhang HHong
3Wong MGMuh Geot
4Jardine MJMeg J
5Hladunewich MMichelle
6Jha VVivek
7Monaghan HHelen
8Zhao MMinghui
9Barbour SSean
10Reich HHeather
11Cattran DDaniel
12Glassock RRichard
13Levin AAdeera
14Wheeler DDavid
15Woodward MMark
16Billot LLaurent
17Chan TMTak Mao
18Liu ZHZhi-Hong
19Johnson DWDavid W
20Cass AAlan

Source PubMed

See all 28 authorsDownload CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Glomerulonephritis, IGAMajor topic
GlucocorticoidsMajor topic
InfectionsMajor topic
MethylprednisoloneMajor topic
Administration, Oral
Adult
Double-Blind Method
Female
Glomerular Filtration Rate
Humans
Kidney Failure, Chronic
Male
Middle Aged
Proteinuria

Source PubMed

Download CSV of topics

Trials5

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01560052Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)Derived from the trialYesClinicalTrials.gov
NCT03468972Effect of Immunosuppression in IgA NephropathyResultsClinicalTrials.gov
NCT04662723Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.ResultsClinicalTrials.gov
NCT04833374Steroids Therapy in IgA Nephropathy With CrescentsResultsClinicalTrials.gov
NCT05528991Oxford Classification and Clinical Remission After Initial Treatments in Patients With IgA NephropathyBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections4

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in28763530Corticosteroids for IgA Nephropathy: TESTING for Benefit, Discovering Harm.https://conductscience.org/library/papers/28763530PubMed
Comment in29159384In patients with proteinuric IgA nephropathy, benefits of methylprednisolone were offset by harms.https://conductscience.org/library/papers/29159384PubMed
Comment in29203129Corticosteroids in IgA Nephropathy.https://conductscience.org/library/papers/29203129PubMed
Comment in29237704TESTING Corticosteroids in IgA Nephropathy: A Continuing Challenge.https://conductscience.org/library/papers/29237704PubMed

Download CSV of comments and corrections

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117513327IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.J Am Soc Nephrol2007https://conductscience.org/library/papers/17513327PubMed
217978307Remission of proteinuria improves prognosis in IgA nephropathy.J Am Soc Nephrol2007https://conductscience.org/library/papers/17978307PubMed
39217756
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)
Lancet1997https://conductscience.org/library/papers/9217756PubMed
422539830Corticosteroid therapy in IgA nephropathy.J Am Soc Nephrol2012https://conductscience.org/library/papers/22539830PubMed
518221258Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China.Nephrology (Carlton)2008https://conductscience.org/library/papers/18221258PubMed
62822795Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man.J Hypertens1987https://conductscience.org/library/papers/2822795PubMed
726630142Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.N Engl J Med2015https://conductscience.org/library/papers/26630142PubMed
819414839A new equation to estimate glomerular filtration rate.Ann Intern Med2009https://conductscience.org/library/papers/19414839PubMed
910093981Corticosteroids in IgA nephropathy: a randomised controlled trial.Lancet1999https://conductscience.org/library/papers/10093981PubMed
1019571791The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification.Kidney Int2009https://conductscience.org/library/papers/19571791PubMed
1123782179IgA nephropathy.N Engl J Med2013https://conductscience.org/library/papers/23782179PubMed
1219628647Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.Nephrol Dial Transplant2009https://conductscience.org/library/papers/19628647PubMed
1325677392Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.J Am Soc Nephrol2015https://conductscience.org/library/papers/25677392PubMed
1418930568Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.Am J Kidney Dis2009https://conductscience.org/library/papers/18930568PubMed
1524892770Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.JAMA2014https://conductscience.org/library/papers/24892770PubMed
1627032886Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.Am J Kidney Dis2016https://conductscience.org/library/papers/27032886PubMed
1725441437GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.Am J Kidney Dis2014https://conductscience.org/library/papers/25441437PubMed
1828363480Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.Lancet2017https://conductscience.org/library/papers/28363480PubMed
1921965586Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population.Nephrol Dial Transplant2012https://conductscience.org/library/papers/21965586PubMed
2024408121Progression of IgA nephropathy under current therapy regimen in a Chinese population.Clin J Am Soc Nephrol2014https://conductscience.org/library/papers/24408121PubMed

See all 23 referencesDownload CSV of references

Cited by279

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 441 citations.

PMIDTitleJournalYearIn PapersSource
42983718IgA nephropathy in a patient with 17α-hydroxylase/17,20-lyase deficiency caused by the CYP17A1 p. Y329fs mutation: a case report and review.BMC Pediatr2026https://conductscience.org/library/papers/42983718PubMed
42968938Targeted-Release Budesonide in Chinese Patients with IgA Nephropathy: A Real-World Retrospective Cohort Study.Drug Des Devel Ther2026https://conductscience.org/library/papers/42968938PubMed
42898794Corticosteroids, serum proteins, and the next phase of precision medicine in IgA nephropathy.Clin Kidney J2026https://conductscience.org/library/papers/42898794PubMed
42756489Clinical remission trajectories and histopathological associations in patients with IgA nephropathy treated with targeted-release budesonide: a real-world cohort study.Front Immunol2026https://conductscience.org/library/papers/42756489PubMed
42709324Effectiveness and Safety of Nefecon in Primary IgA Nephropathy Across Different Baseline Proteinuria Levels: A Real-World Study.Adv Ther2026https://conductscience.org/library/papers/42709324PubMed
42688466Efficacy and safety of Nefecon, glucocorticoids, or supportive therapyadded to RASi+SGLT2i in IgA nephropathy.Front Pharmacol2026https://conductscience.org/library/papers/42688466PubMed
42675083Large language models decode narrative pathology reports to define clinically relevant subtypes in IgA nephropathy.Nat Commun2026https://conductscience.org/library/papers/42675083PubMed
42621401Telitacicept for IgA nephropathy: a systematic review and meta-analysis of observational studies.Front Med (Lausanne)2026https://conductscience.org/library/papers/42621401PubMed
42523835Case Report: Successful telitacicept treatment for IgA nephropathy with stage 4 chronic kidney disease and acute renal failure.Front Immunol2026https://conductscience.org/library/papers/42523835PubMed
42483540IgA nephropathy management: what does the future hold?Kidney Int Suppl (2011)2026https://conductscience.org/library/papers/42483540PubMed
42483537Management of IgA nephropathy and the expanding role of immunomodulation.Kidney Int Suppl (2011)2026https://conductscience.org/library/papers/42483537PubMed
42421973Biomarkers predicting good prognosis among patients receiving immunosuppressive treatment in IgA nephropathy: the promising role of serum TGF-β1 and MCP-1.Front Immunol2026https://conductscience.org/library/papers/42421973PubMed
42415613Evolving therapeutic landscape of immunoglobulin A nephropathy: targeted immune pathways and novel therapies.Kidney Res Clin Pract2026https://conductscience.org/library/papers/42415613PubMed
42292450Real-world study of telitacicept in the treatment of IgA nephropathy.Front Immunol2026https://conductscience.org/library/papers/42292450PubMed
42243722FMultifunctional magnetic resonance imaging for the assessment of renal pathological alterations in IgA nephropathy.BMC Nephrol2026https://conductscience.org/library/papers/42243722PubMed
42216130Clinicopathological characteristics and renal outcomes of IgA nephropathy in systemic lupus erythematosus: a case report and systematic literature review.BMC Nephrol2026https://conductscience.org/library/papers/42216130PubMed
42087286Yi-Shen-Hua-Shi granule added to supportive care reduces proteinuria in IgA nephropathy: a multicenter randomized controlled trial.Ren Fail2026https://conductscience.org/library/papers/42087286PubMed
42032511Reshaping the therapeutic landscape of IgA nephropathy: a Bayesian network meta-analysis on the comparative efficacy and safety of immunosuppressants and targeted agents.BMC Nephrol2026https://conductscience.org/library/papers/42032511PubMed
41882420The epidemiology of kidney and urinary tract infections in pediatric chronic kidney disease: prevalence, risk factors and association with GFR decline in the Chronic Kidney Disease in Children Study.Pediatr Nephrol2026https://conductscience.org/library/papers/41882420PubMed
41840527Efficacy and safety of supportive and immunosuppressive therapies in the treatment of lgA nephropathy: a network Meta-analysis of randomized clinical trials.BMC Nephrol2026https://conductscience.org/library/papers/41840527PubMed

See all 279 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
REN5972PubTator's text mininghttps://conductscience.org/library/genes/5972

Source NCBI Gene

Download CSV of genes

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CYCLOPHOSPHAMIDECHEMBL1200796Results1https://conductscience.org/library/drugs/CHEMBL1200796ChEMBL
AZATHIOPRINECHEMBL1542Results1https://conductscience.org/library/drugs/CHEMBL1542ChEMBL
METHYLPREDNISOLONECHEMBL650Results2https://conductscience.org/library/drugs/CHEMBL650ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28763548

GET https://conductscience.org/api/papers/v1/28763548/authors?page=2